The stock of Eli Lilly and Company (LLY) has declined 1.7% already this week, losing almost $14 billion of its market value. Earlier this month, the FDA removed Lilly’s popular GLP-1 drug tirzepatide from its shortage list after confirming with Lilly that it can meet the present and future demand with its manufacturing expansion. Lilly markets tirzepatide as Mounjaro for type II diabetes and Zepbound for obesity. Due to increased demand, tirzepatide was added to the FDA’s shortage list in 2022.In the United ...

These innovative drugmakers have potential catalysts ahead.Once a company's shares rise rapidly, investors might wonder if it's still worth investing in the stock. The answer is that it depends. Some companies' strong performances are short-lived. Others perform well because they have attractive businesses that can deliver outsized returns in the long run. Those in the second category are worth investing in even after an impressive run.Let's look at two examples: Eli Lilly (LLY 1.34%) and Sarepta Therapeuti ...

Eli Lilly is investing billions into new research and manufacturing capabilities.Over the last couple of years, pharmaceutical giant Eli Lilly (LLY 0.34%) has made a splash in the red-hot weight loss space. The company's path-breaking innovation in using glucagon-like peptide-1 (GLP-1) agonists, Mounjaro and Zepbound, are just two of the company's blockbuster drugs helping pave the way in diabetes and obesity care, respectively.Lilly's success in the weight loss realm isn't without hiccups, though.  The com ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.Eli Lilly (LLY -0.74%) is the most valuable healthcare stock in the world, with a market capitalization north of $800 billion. In the past 12 months, its shares have risen by more than 50%, and while its growth prospects look strong, investors may balk at paying a multiple of more than 100 times its trailing earnings.However, while Eli Lilly's valuation may look pricey, that shouldn't diss ...

Results from Lilly's "Urgent Conversations" survey reinforce the work by the Crohn's & Colitis Foundation of America, including the "We Can't Wait" mobile bathroom finder appINDIANAPOLIS, Oct. 16, 2024 /PRNewswire/ -- Results from the national "Urgent Conversations" survey, announced today by Eli Lilly and Company (NYSE: LLY), found that over half (60%) of the general population struggle to find a public restroom, a challenge that is even more pronounced (84%) for people with ulcerative colitis (UC).1 This ...

文章核心观点 - 艾利利利用人工智能(AI)技术来提高研发效率和生产效率,以保持在技术领域的领先地位 [1][2][3][4][5] - 公司任命了首席AI官员,负责制定和实施公司的AI战略 [1][2] 研发活动 - 公司目前有50多个管线项目处于临床试验阶段,AI可以大幅简化监管申报等耗时活动 [3] - AI可以帮助指导药物发现过程,提高成功率,公司已与一家AI驱动的生物科技公司建立合作 [4] 其他应用 - AI还可以应用于制造和临床试验管理,提高运营效率 [5] - 新任首席AI官员需要一些时间来实现重大效率提升,但前景乐观 [5]

These are two of healthcare's biggest darlings right now, but one looks better positioned for the long run.Glucagon-like peptide-1 (GLP-1) agonists have taken the healthcare world by storm, emerging as mainstream treatments for patients with diabetes or obesity. Some of these medications include Novo Nordisk's (NVO -1.65%) Ozempic, Wegovy, Rybelsus, and Saxenda, and Eli Lilly's (LLY -1.74%) Mounjaro and Zepbound.Below, I'll dig into which pharmaceutical stock I think is the better buy for the long run. Whil ...

Lilly has invested billions of dollars to ramp up production capacity.Eli Lilly (LLY -1.74%) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs. Lilly sells the compound tirzepatide under two different names -- Mounjaro for type 2 diabetes and Zepbound for weight loss. But doctors have prescribed either for the weight loss indication. These drugs have become blockbusters, bringing in mor ...

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024.LONDON — U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K.The weight-loss treatment firm and creator of Zepbound announced Monday that it would commit £279 million ($364 million) to help tackle Britain's significant health challenges — including obesity.The "strategic collaboration," agreed with the ...

文章核心观点 - 新数据显示,与使用 ustekinumab 相比,更多接受 mirikizumab 治疗的中重度活动性克罕病患者在第52周实现了组织学缓解 [1][2] - 这是首次在克罕病临床试验中报告使用系统评估五个肠段(四个结肠和一个回肠)的组织学和联合组织学-内窥镜结果,符合欧洲克罕病和结肠炎学会(ECCO)最新发布的黏膜组织病理学声明 [1][4] - 这些数据进一步证实了 mirikizumab 在帮助克罕病患者实现更深层次的黏膜愈合方面的潜力 [2] 关键要点总结 1. 组织学缓解 - 在VIVID-1试验中,与安慰剂相比,mirikizumab在第12周和第52周均显示在所有组织学和组织学-内窥镜终点上均有名义上的统计学显著改善 [2] - 在整体人群中,第52周时接受 mirikizumab 治疗的患者中有更多人实现了组织学缓解(58.2%比48.8%;p=0.0075) [2] - 在基线时有活跃性组织学疾病且至少有1次生物制剂治疗失败的患者中,mirikizumab也显示在第52周有更高的组织学缓解率(56.5%比41.3%;p=0.0064)和内窥镜-组织学缓解率(39.6%比27.8%;p=0.024) [2] 2. 安全性 - mirikizumab在中重度活跃性克罕病患者中的总体安全性与在溃疡性结肠炎患者中的已知安全性一致 [3] - 严重不良事件的发生率在安慰剂组高于 mirikizumab 组 [3] - 最常见的不良事件包括COVID-19、贫血、关节痛、头痛、上呼吸道感染、鼻咽炎和注射部位反应 [3] 3. 监管进展 - 礼来已在全球范围内(包括美国、欧洲、日本和中国)提交了 mirikizumab 用于治疗克罕病的上市申请,并计划进行更多全球监管提交 [4] - 礼来正在研究 mirikizumab 在儿童和成人克罕病患者中的长期疗效和安全性 [5] 4. 其他适应症 - mirikizumab 已获批用于治疗成人中重度活跃性溃疡性结肠炎,商品名为 Omvoh [6][15] - 礼来正在进行多项 mirikizumab 在溃疡性结肠炎适应症的临床试验,包括儿童患者和成人长期疗效及安全性研究 [6]